Literature DB >> 20202800

Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).

Wolfgang Gaebel1, Mathias Riesbeck, Martina von Wilmsdorff, Tom Burns, Eske M Derks, René S Kahn, Wulf Rössler, W Wolfgang Fleischhacker.   

Abstract

Effectiveness has become more and more important as a comprehensive outcome measure for (long-term) treatment in schizophrenia. Early predictors to identify patients at a high risk for not succeeding the initiated treatment would be very useful. Discontinuation of the initiated treatment was used as criterion for effectiveness and patients' drug attitude was shown to be predictive for non-adherence or discontinuation of long-term treatment in schizophrenia. Accordingly, the predictive validity of the Drug Attitude Inventory (DAI) for effectiveness should be evaluated. Based on a sub-sample of patients from the EUFEST study for whom DAI assessments were available significant predictors for effectiveness as measured by discontinuation of initiated treatment were identified based on a logistic and a Cox-regression analysis. A Receiver-Operating Characteristic- (ROC-) analysis was conducted for the DAI, prognostic / diagnostic parameters (sensitivity, specificity) were calculated and a cut-off value suggested. In a sample of 228 first-episode patients, the DAI score was the most powerful predictor for effectiveness (p<0.001) besides two other significant predictors (PANSS-positive score and sexual side effects). The ROC-analysis revealed an area under the curve of 0.64 (p<0.001). The suggested cut-off point of about 20 yielded a sensitivity of 70-75% and a specificity of 40-45%. Study results indicate that the Drug Attitude Inventory, filled in by patients early in treatment seems to be a valid predictor for effectiveness as measured by discontinuation of the initiated treatment. DAI scores could also serve as an (differential) indicator for the need of enhanced treatment monitoring. These findings have to be validated in other (first-episode) samples. 2010 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20202800     DOI: 10.1016/j.euroneuro.2010.02.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  14 in total

Review 1.  Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.

Authors:  A George Awad
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

2.  Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.

Authors:  Pál Czobor; Richard A Van Dorn; Leslie Citrome; Rene S Kahn; W Wolfgang Fleischhacker; Jan Volavka
Journal:  Eur Neuropsychopharmacol       Date:  2015-04-30       Impact factor: 4.600

3.  Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?

Authors:  Stephen M Lawrie; Bayanne Olabi; Jeremy Hall; Andrew M McIntosh
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

4.  Second-generation antipsychotic discontinuation in first episode psychosis: an updated review.

Authors:  Brian J Miller; Chelsea Bodenheimer; Krystle Crittenden
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-08-31       Impact factor: 2.582

5.  Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention.

Authors:  Richard J Drake; Merete Nordentoft; Gillian Haddock; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; Stefan Leucht; Markus Leweke; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Iris E Sommer; René S Kahn; Shon W Lewis
Journal:  Schizophr Bull       Date:  2015-03-05       Impact factor: 9.306

Review 6.  Amisulpride versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Joaquim I Silveira da Mota Neto; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 7.  Ziprasidone versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Sandra Schwarz; Paranthaman Seth S Bhoopathi; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

8.  Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia.

Authors:  Matthias J Müller
Journal:  Schizophr Res Treatment       Date:  2011-10-27

9.  Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan.

Authors:  Wenyu Ye; Haya Ascher-Svanum; Yuka Tanji; Jennifer A Flynn; Michihiro Takahashi
Journal:  Patient Prefer Adherence       Date:  2011-12-14       Impact factor: 2.711

10.  Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.

Authors:  Haya Ascher-Svanum; William S Montgomery; David P McDonnell; Kristina A Coleman; Peter D Feldman
Journal:  Int J Gen Med       Date:  2012-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.